Jaguar Animal Health (NASDAQ:JAGX) Posts Quarterly Earnings Results, Beats Expectations By $36.45 EPS

Jaguar Animal Health (NASDAQ:JAGX) released its earnings results on Wednesday. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($52.15) by $36.45, Zacks reports.

Jaguar Animal Health Trading Down 3.1%

Shares of JAGX traded down $0.03 during mid-day trading on Wednesday, hitting $0.95. The company’s stock had a trading volume of 177,397 shares, compared to its average volume of 106,993. Jaguar Animal Health has a 1-year low of $0.72 and a 1-year high of $85.40. The firm has a market capitalization of $567,600.00, a P/E ratio of -0.00 and a beta of -0.06. The firm has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $9.51.

Analysts Set New Price Targets

Several research analysts have issued reports on JAGX shares. Wall Street Zen upgraded Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.